Edgewise Therapeutics, Inc.
Nasdaq EWTX · Boulder, CO
Works in Cardiovascular · Genetic & rare · Musculoskeletal · Neurology
Edgewise Therapeutics, Inc. is a clinical trial sponsor based in Boulder, CO, listed as Nasdaq EWTX. It has 5 active clinical trials with 548 planned participants, in Cardiovascular, Genetic & rare, Musculoskeletal and Neurology. Since 2021 it has completed 12 trials and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq EWTX
Pipeline · 5 active trials
| Stage | Trial | Status |
|---|---|---|
On the market · 0 products
No marketed products under this name.
Questions about Edgewise Therapeutics, Inc
Edgewise Therapeutics, Inc is lead sponsor of 5 active clinical trials on ClinicalTrials.gov, with 548 planned participants, in Cardiovascular, Genetic & rare, Musculoskeletal, Neurology. Since 2021 it has completed 12 trials and stopped 0 early.
Edgewise Therapeutics, Inc is based in Boulder, CO and is listed as Nasdaq EWTX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Edgewise Therapeutics, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-13.
Products come from FDA's drug application database and, for vaccines, cell and gene therapies and blood products, FDA's Purple Book of licensed biologics; checked 2026-09-24.
Approve Suite is not affiliated with Edgewise Therapeutics, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.